Tamoxifen reduces breast cancer rates by nearly a third for 20 years

11 diciembre 2014

The preventive effect of breast cancer drug ‘tamoxifen’ remains virtually constant for at least 20 years – with rates reduced by around 30 per cent – a new analysis reveals. During the study 7,154 pre and post-menopausal women were randomized to receive either tamoxifen (20mg daily) or a matching placebo for five years. After completing treatment, the health of all participants was monitored with an average follow-up time of 16 years and maximum of 22 years.